JP6283031B2 - 遺伝学的に修飾された非ヒト動物およびその使用法 - Google Patents

遺伝学的に修飾された非ヒト動物およびその使用法 Download PDF

Info

Publication number
JP6283031B2
JP6283031B2 JP2015531224A JP2015531224A JP6283031B2 JP 6283031 B2 JP6283031 B2 JP 6283031B2 JP 2015531224 A JP2015531224 A JP 2015531224A JP 2015531224 A JP2015531224 A JP 2015531224A JP 6283031 B2 JP6283031 B2 JP 6283031B2
Authority
JP
Japan
Prior art keywords
human
cells
genetically modified
mice
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015531224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529083A (ja
JP2015529083A5 (show.php
Inventor
リチャード エイ． フラベル
リチャード エイ． フラベル
マルクス マンツ
マルクス マンツ
アンソニー ロンヴォークス
アンソニー ロンヴォークス
ティル ストロウィッグ
ティル ストロウィッグ
ティム ウィリンガー
ティム ウィリンガー
アンドリュー ジェイ． マーフィー
アンドリュー ジェイ． マーフィー
ショーン スティーブンズ
ショーン スティーブンズ
ジョージ ヤンコポーロス
ジョージ ヤンコポーロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Regeneron Pharmaceuticals Inc
Original Assignee
Yale University
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Regeneron Pharmaceuticals Inc filed Critical Yale University
Publication of JP2015529083A publication Critical patent/JP2015529083A/ja
Publication of JP2015529083A5 publication Critical patent/JP2015529083A5/ja
Application granted granted Critical
Publication of JP6283031B2 publication Critical patent/JP6283031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015531224A 2012-09-07 2013-09-06 遺伝学的に修飾された非ヒト動物およびその使用法 Active JP6283031B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698002P 2012-09-07 2012-09-07
US61/698,002 2012-09-07
US201361775171P 2013-03-08 2013-03-08
US61/775,171 2013-03-08
PCT/US2013/058448 WO2014039782A2 (en) 2012-09-07 2013-09-06 Genetically modified non-human animals and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018010192A Division JP6517958B2 (ja) 2012-09-07 2018-01-25 遺伝学的に修飾された非ヒト動物およびその使用法

Publications (3)

Publication Number Publication Date
JP2015529083A JP2015529083A (ja) 2015-10-05
JP2015529083A5 JP2015529083A5 (show.php) 2017-10-05
JP6283031B2 true JP6283031B2 (ja) 2018-02-21

Family

ID=50237767

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015531224A Active JP6283031B2 (ja) 2012-09-07 2013-09-06 遺伝学的に修飾された非ヒト動物およびその使用法
JP2018010192A Active JP6517958B2 (ja) 2012-09-07 2018-01-25 遺伝学的に修飾された非ヒト動物およびその使用法
JP2019079029A Active JP6732998B2 (ja) 2012-09-07 2019-04-18 遺伝学的に修飾された非ヒト動物およびその使用法
JP2020117482A Active JP7066785B2 (ja) 2012-09-07 2020-07-08 遺伝学的に修飾された非ヒト動物およびその使用法
JP2022072893A Active JP7605789B2 (ja) 2012-09-07 2022-04-27 遺伝学的に修飾された非ヒト動物およびその使用法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018010192A Active JP6517958B2 (ja) 2012-09-07 2018-01-25 遺伝学的に修飾された非ヒト動物およびその使用法
JP2019079029A Active JP6732998B2 (ja) 2012-09-07 2019-04-18 遺伝学的に修飾された非ヒト動物およびその使用法
JP2020117482A Active JP7066785B2 (ja) 2012-09-07 2020-07-08 遺伝学的に修飾された非ヒト動物およびその使用法
JP2022072893A Active JP7605789B2 (ja) 2012-09-07 2022-04-27 遺伝学的に修飾された非ヒト動物およびその使用法

Country Status (18)

Country Link
US (6) US9820476B2 (show.php)
EP (3) EP4193834B1 (show.php)
JP (5) JP6283031B2 (show.php)
KR (7) KR102473555B1 (show.php)
CN (4) CN113897398B (show.php)
AU (3) AU2013312359B8 (show.php)
CA (1) CA2881468C (show.php)
DK (1) DK2892330T3 (show.php)
ES (2) ES2938342T3 (show.php)
FI (1) FI2892330T3 (show.php)
IL (4) IL282472B2 (show.php)
IN (1) IN2015DN02032A (show.php)
MX (2) MX364714B (show.php)
NZ (3) NZ746089A (show.php)
PT (1) PT2892330T (show.php)
RU (2) RU2768282C2 (show.php)
SG (2) SG11201500504RA (show.php)
WO (1) WO2014039782A2 (show.php)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
EP3375284B1 (en) 2011-02-15 2023-03-29 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice and uses thereof
CA2881468C (en) 2012-09-07 2023-03-21 Yale University Genetically modified mice which express human cytokines and methods of use thereof, including engraftment
NZ724353A (en) * 2012-11-05 2022-05-27 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI2908626T1 (sl) 2013-10-15 2017-02-28 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
AU2014353347B2 (en) 2013-11-19 2020-07-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
SG11201608696RA (en) 2014-05-05 2016-11-29 Regeneron Pharma Humanized c5 and c3 animals
NO2785538T3 (show.php) 2014-05-07 2018-08-04
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
WO2016089692A1 (en) 2014-12-05 2016-06-09 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
CA2968675C (en) 2014-12-09 2023-10-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
HK1245010A1 (zh) 2014-12-10 2018-08-24 明尼苏达大学董事会 用於治疗疾病的遗传修饰的细胞、组织和器官
CN115943929B (zh) 2015-04-13 2025-01-10 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
US10306874B2 (en) 2015-11-20 2019-06-04 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
MX2018009513A (es) 2016-02-04 2019-01-31 Regeneron Pharma Animales no humanos que tienen un gen angptl8 modificado genéticamente.
EP3422845B1 (en) 2016-02-29 2021-06-02 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
CN106119284A (zh) * 2016-06-27 2016-11-16 北京维通达生物技术有限公司 一种用于构建免疫缺陷动物模型的产品及其应用
WO2018102546A1 (en) * 2016-11-30 2018-06-07 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
JP7129426B2 (ja) * 2017-05-12 2022-09-01 ザ ジャクソン ラボラトリー Ｍｈｃクラスｉおよびｍｈｃクラスｉｉを欠損しているｎｓｇマウス
AU2019308205B2 (en) 2018-07-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
WO2020068615A1 (en) * 2018-09-24 2020-04-02 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111118019B (zh) * 2018-12-25 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il3基因改造非人动物的构建方法及应用
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
US20220354098A1 (en) * 2019-07-17 2022-11-10 Yale University Genetically Modified Non-Human Animals and Methods of Use Thereof
WO2021083366A1 (en) * 2019-11-01 2021-05-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with human or chimeric thpo
US11339279B2 (en) * 2020-04-01 2022-05-24 Chevron Phillips Chemical Company Lp Dual catalyst system for producing LLDPE and MDPE copolymers with long chain branching for film applications
WO2022222958A1 (en) * 2021-04-20 2022-10-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
EP4557944A1 (en) 2022-07-19 2025-05-28 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
CN121335619A (zh) 2023-06-16 2026-01-13 瑞泽恩制药公司 载体、经基因修饰的细胞和包含其的经基因修饰的非人动物
WO2025171307A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
DE3853201T2 (de) 1987-12-23 1995-09-14 Univ Leland Stanford Junior Schimäre immunkompromittierende Säugetiere und ihre Verwendung.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
DE69131331T2 (de) 1990-01-15 2000-03-02 Yeda Research And Development Co., Ltd. Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
CA2063408A1 (en) 1990-05-03 1991-11-04 Susan Mayo Human lymphoid tissue in an immunocompromised host
WO1991018615A1 (en) 1990-05-25 1991-12-12 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
JPH06505186A (ja) 1991-02-11 1994-06-16 オマーヤ，アユブ　ケー． 脊髄液駆動式人工器官
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
CA2195678A1 (en) 1994-07-27 1996-02-08 Joseph A. Borkowski Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
EP0973381B1 (en) 1997-04-09 2010-03-03 AMDL, Inc. Animal model for evaluation of vaccines
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
WO2001015521A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
CA2392740A1 (en) 1999-12-09 2001-06-14 Human Genome Sciences, Inc. Il-6 like polynucleotides, polypeptides, and antibodies
AU2001290855A1 (en) 2000-09-14 2002-03-26 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2453531A1 (en) * 2001-07-10 2003-01-23 Johnson & Johnson Research Pty Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1452093A4 (en) 2001-11-15 2007-08-15 Kirin Brewery CHIMESE NON-MENTAL ANIMAL
AU2003281309A1 (en) 2002-07-05 2004-01-23 Kirin Beer Kabushiki Kaisha Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
WO2004022738A1 (en) 2002-09-09 2004-03-18 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
ATE401787T1 (de) 2002-12-16 2008-08-15 Genentech Inc Menschliches cd20 exprimierende transgene mäuse
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
SI2019683T2 (sl) 2006-04-25 2022-10-28 The Regents Of The University Of California Dajanje rastnih faktorjev za zdravljenje motenj CŽS
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
WO2008153742A2 (en) 2007-05-23 2008-12-18 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20110118446A1 (en) 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
EP2449094A4 (en) * 2009-06-29 2013-07-10 Qingfeng Chen METHOD FOR PRODUCING HUMANIZED NON-MAMMAL MAMMALS
US20120251528A1 (en) 2009-06-29 2012-10-04 Leskov Ilya B Non-Human Mammal Model Of Human Hematopoietic Cancer
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
EP2618656B1 (en) 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
EP3375284B1 (en) 2011-02-15 2023-03-29 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice and uses thereof
HUE033400T2 (en) 2011-10-28 2017-12-28 Regeneron Pharma Humanized IL-6 and IL-6 receptor
CA2881468C (en) 2012-09-07 2023-03-21 Yale University Genetically modified mice which express human cytokines and methods of use thereof, including engraftment
NZ724353A (en) 2012-11-05 2022-05-27 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI2908626T1 (sl) 2013-10-15 2017-02-28 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
CN115943929B (zh) 2015-04-13 2025-01-10 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法

Also Published As

Publication number Publication date
EP2892330A2 (en) 2015-07-15
IL307969B2 (en) 2026-02-01
IL282472A (en) 2021-06-30
CN104955326A (zh) 2015-09-30
KR102340059B1 (ko) 2021-12-17
KR102287541B1 (ko) 2021-08-10
MX2019005251A (es) 2019-08-05
WO2014039782A2 (en) 2014-03-13
JP2018088925A (ja) 2018-06-14
CA2881468C (en) 2023-03-21
RU2768282C2 (ru) 2022-03-23
PT2892330T (pt) 2023-02-17
JP6732998B2 (ja) 2020-07-29
JP2020168024A (ja) 2020-10-15
NZ704957A (en) 2018-05-25
US20200093105A1 (en) 2020-03-26
ES2938342T3 (es) 2023-04-10
US20210368752A1 (en) 2021-12-02
AU2019216625B2 (en) 2021-07-08
CN120718856A (zh) 2025-09-30
KR102473555B1 (ko) 2022-12-05
US20250072405A1 (en) 2025-03-06
EP2892330B1 (en) 2022-11-23
JP7605789B2 (ja) 2024-12-24
IL236877A0 (en) 2015-03-31
IL265570A (en) 2019-05-30
AU2013312359A1 (en) 2015-02-19
AU2013312359B8 (en) 2019-08-15
US20190082663A1 (en) 2019-03-21
FI2892330T3 (fi) 2023-03-25
KR20150052274A (ko) 2015-05-13
KR20230153500A (ko) 2023-11-06
SG11201500504RA (en) 2015-02-27
US12127537B2 (en) 2024-10-29
KR20220164808A (ko) 2022-12-13
ES3034290T3 (en) 2025-08-14
EP4193834B1 (en) 2025-05-14
RU2017145913A3 (show.php) 2021-08-16
JP2015529083A (ja) 2015-10-05
US10433527B2 (en) 2019-10-08
IL307969A (en) 2023-12-01
CA2881468A1 (en) 2014-03-13
DK2892330T3 (da) 2023-01-30
IL282472B2 (en) 2024-04-01
JP7066785B2 (ja) 2022-05-13
US11026408B2 (en) 2021-06-08
MX2015002983A (es) 2015-06-17
US20150208622A1 (en) 2015-07-30
MX385035B (es) 2025-03-14
HK1211176A1 (en) 2016-05-20
JP6517958B2 (ja) 2019-05-22
NZ746089A (en) 2020-05-29
WO2014039782A3 (en) 2015-07-23
EP4606818A2 (en) 2025-08-27
US20180020647A1 (en) 2018-01-25
JP2022105531A (ja) 2022-07-14
SG10201701759VA (en) 2017-04-27
CN104955326B (zh) 2018-07-20
JP2019110922A (ja) 2019-07-11
US9820476B2 (en) 2017-11-21
EP4193834C0 (en) 2025-05-14
AU2021240324A1 (en) 2021-10-28
KR20210156846A (ko) 2021-12-27
CN113897398A (zh) 2022-01-07
CN108782459B (zh) 2021-11-05
NZ741951A (en) 2020-04-24
AU2021240324B2 (en) 2024-02-22
EP4606818A3 (en) 2025-10-22
AU2013312359A8 (en) 2019-08-15
KR20210044315A (ko) 2021-04-22
MX364714B (es) 2019-05-06
KR102594390B1 (ko) 2023-10-27
AU2013312359B2 (en) 2019-05-23
EP2892330A4 (en) 2016-07-27
IL282472B1 (en) 2023-12-01
RU2642319C2 (ru) 2018-01-24
RU2017145913A (ru) 2019-02-19
AU2019216625A1 (en) 2019-09-05
KR20210099664A (ko) 2021-08-12
EP4193834A1 (en) 2023-06-14
IN2015DN02032A (show.php) 2015-08-14
CN113897398B (zh) 2025-07-08
IL265570B (en) 2021-05-31
KR102645622B1 (ko) 2024-03-11
KR20240045263A (ko) 2024-04-05
RU2015112607A (ru) 2016-10-27
IL307969B1 (en) 2025-10-01
KR102241962B1 (ko) 2021-04-20
CN108782459A (zh) 2018-11-13

Similar Documents

Publication Publication Date Title
JP7605789B2 (ja) 遺伝学的に修飾された非ヒト動物およびその使用法
HK40095010B (en) Methods of using genetically modified mice
HK40095010A (en) Methods of using genetically modified mice
HK1211176B (en) Genetically modified mice and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170822

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180125

R150 Certificate of patent or registration of utility model

Ref document number: 6283031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250